Current Report Filing (8-k)
December 06 2016 - 7:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 6, 2016
MATEON THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
|
0-21990
|
|
13-3679168
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
701 Gateway Boulevard, Suite 210,
South San Francisco, CA
|
|
94080
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 635-7000
N/A
Former Name or
Former Address, if Changed Since Last Report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On December 6, 2016, Mateon Therapeutics, Inc. (Mateon) issued a press
release announcing the presentation of OXi4503 acute myeloid leukemia (AML) study data at the 58
th
Annual Meeting of the American Society of Hematology. OXi4503 is one of Mateons two
vascular disrupting agents (VDAs) currently in clinical development.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
The following exhibit is furnished with this report:
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release dated December 6, 2016.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Mateon Therapeutics, Inc.
|
|
|
|
Date: December 6, 2016
|
|
|
|
/s/ Matthew M. Loar
|
|
|
|
|
By:
|
|
Matthew M. Loar
|
|
|
|
|
|
|
Chief Financial Officer
|